UC Davis-enabled neuroscience startup Delix Therapeutics announced the regulatory approval and initiation of recruitment of a phase I clinical trial of lead candidate, DLX-001, a non-hallucinogenic psychoplastogen.
In a press release, the company stated the lead candidate is the first of several psychoplastogens in the Delix platform to be approved for human trials. Delix’s approach is based on the work of company co-founder and Chief Innovation Officer David E. Olson at the University of California, Davis, who discovered several novel psychoplastogens that have significant therapeutic potential in preclinical models, without hallucinogenic side effects inherent in first and second generation psychedelic psychoplastogens.
Read more here.
